How many insider trades does FilingIQ track for NKTR?

FilingIQ tracks 932 Form 4 insider transactions for NKTR (NEKTAR THERAPEUTICS), covering filings from Jan 13, 2015 onwards. 2 of those were filed in the last 90 days.

Are NKTR insiders net buyers or net sellers?

Across the full Form 4 history for NKTR, 6 transactions (1%) were open-market purchases and 395 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NKTR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NKTR in?

NEKTAR THERAPEUTICS (NKTR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.03B.

NKTR insider trading

NasdaqCM Healthcare

NEKTAR THERAPEUTICS — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

932

Last 90 days

Buys / sells

1% / 42%

Market cap

$2.03B

About NEKTAR THERAPEUTICS

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Company website: www.nektar.com

NKTR insider activity at a glance

FilingIQ has scored 932 insider transactions for NKTR since Jan 13, 2015. The most recent filing in our index is dated Feb 18, 2026.

Across the full history, 6 open-market purchases and 395 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NKTR insider trades is 55.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NKTR trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for NKTR?: FilingIQ tracks 932 Form 4 insider transactions for NKTR (NEKTAR THERAPEUTICS), covering filings from Jan 13, 2015 onwards. 2 of those were filed in the last 90 days.
Are NKTR insiders net buyers or net sellers?: Across the full Form 4 history for NKTR, 6 transactions (1%) were open-market purchases and 395 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NKTR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NKTR in?: NEKTAR THERAPEUTICS (NKTR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.03B.

Methodology & sources

Every NKTR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.